Ultimovacs Announces First Patient Randomized in Phase II LUNGVAC Trial of UV1 in Non-Small Cell Lung Cancer (NSCLC)
October 25, 2022 02:00 ET
|
Ultimovacs ASA
Fifth phase II trial assessing the impact of UV1 in various immunotherapy combinationsEnrollment of 138 patients at approximately all lung cancer centers in NorwayNon-small cell lung cancer is one of...
Ultimovacs Announces New UV1 Data Showing Enhanced Efficacy Including in Hard-to-Treat Cancer Patients, Supporting Broad Utility
October 18, 2022 02:00 ET
|
Ultimovacs ASA
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Biomarker data support strong clinical responses from UV1 in combination...
Ultimovacs Announces Positive Three-Year Results of 71% Overall Survival Rate in Cohort 1 of UV1-103 Study in Metastatic Malignant Melanoma
October 05, 2022 13:26 ET
|
Ultimovacs ASA
Malignant melanoma patients treated with immunotherapy combination UV1 and pembrolizumab in phase I clinical trialConsistently high overall survival (OS) rate: 71% at three-year follow-up of patients...
Ultimovacs Announces Plenary Oral Presentation of Phase I Melanoma Trial Results at the 19th International Congress of the Society for Melanoma Research (SMR)
September 21, 2022 10:30 ET
|
Ultimovacs ASA
New clinical data from phase I trial UV1-103, combining UV1 with pembrolizumab in advanced melanoma will be presented Oslo, September 21 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical...
Ultimovacs Announces Publication of Phase I Melanoma Trial Data in Journal of Translational Medicine
September 12, 2022 09:05 ET
|
Ultimovacs ASA
Comprehensive characterization of phase I UV1-checkpoint inhibitor combination trialClinical responses seen in patients with favored and less favored baseline characteristicsT cell activation observed...
Ultimovacs ASA: New share capital registered
September 09, 2022 02:53 ET
|
Ultimovacs ASA
Oslo, 9 September 2022, Ultimovacs ASA (the "Company") refers to the announcement published on 5 September 2022 regarding the issuance of new shares in connection with the Company's employee incentive...
Ultimovacs ASA: Mandatory notification of trade by primary insider
September 05, 2022 13:00 ET
|
Ultimovacs ASA
Oslo, 05 September 2022, Carlos de Sousa, Chief Executive Officer and primary insider in Ultimovacs ASA, has today bought 2,000 shares in the company at an average price of NOK 67.10 per share....
Ultimovacs ASA: Share capital increase related to exercise of options
September 05, 2022 10:30 ET
|
Ultimovacs ASA
Oslo, 05 September 2022, the Board of Directors of Ultimovacs ASA (the "Company") has resolved to increase the Company's share capital by NOK 4,400 through the issuance of 44,000 new shares, each with...
Ultimovacs Strengthens IP Portfolio with the United States Patent and Trademark Office (USPTO) Notice of Allowance on UV1 Method Patent
August 22, 2022 11:00 ET
|
Ultimovacs ASA
Will cover methods for eliciting T cell immune responseProtects US sales and marketing of UV1 Oslo, August 22, 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in...
Ultimovacs ASA Reports Second Quarter 2022 Financial Results and Provides General Business Update
August 19, 2022 02:00 ET
|
Ultimovacs ASA
Oslo, August 19, 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announces its second quarter 2022 results today. The presentation by...